Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
311 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2014', provides an overview of the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview 11 Therapeutics Development 12 Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Overview 12 Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis 13 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Development by Companies 14 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Investigation by Universities/Institutes 19 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Products Glance 20 Late Stage Products 20 Clinical Stage Products 21 Early Stage Products 22 Unknown Stage Products 23 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Development by Companies 24 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Investigation by Universities/Institutes 30 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Companies Involved in Therapeutics Development 31 A. Menarini Industrie Farmaceutiche Riunite Srl 31 Adamis Pharmaceuticals Corporation 32 Aeterna Zentaris Inc. 33 Alethia Biotherapeutics Inc. 34 Amgen Inc. 35 AnGes MG, Inc. 36 Antoxis Limited 37 Aphios Corporation 38 Armour Therapeutics Inc. 39 Arno Therapeutics, Inc. 40 Astellas Pharma Inc. 41 Astex Pharmaceuticals, Inc. 42 AstraZeneca PLC 43 Ausio Pharmaceuticals, LLC 44 Bavarian Nordic A/S 45 Bayer AG 46 Beta Pharma, Inc. 47 Bio-Cancer Treatment International Limited 48 Biscayne Pharmaceuticals, Inc. 49 Boehringer Ingelheim GmbH 50 Celldex Therapeutics, Inc. 51 CureTech Ltd. 52 CytoVac A/S 53 DexTech Medical AB 54 Enceladus Pharmaceuticals BV 55 Endo Pharmaceuticals Inc. 56 EndoCeutics, Inc. 57 Endocyte, Inc. 58 Errant Gene Therapeutics, LLC 59 Fujifilm Corporation 60 Genentech, Inc. 61 Glactone Pharma AB 62 GlaxoSmithKline plc 63 GTx, Inc. 64 Harbor Therapeutics, Inc. 65 Hybrigenics S.A. 66 Incuron, LLC 67 Io Therapeutics, Inc. 68 Isis Pharmaceuticals, Inc. 69 Johnson & Johnson 70 Kinex Pharmaceuticals, LLC 71 Medivation, Inc. 72 Medvio Eurasia 73 Merck KGaA 74 Millennium Pharmaceuticals, Inc. 75 NewLink Genetics Corporation 76 Novartis AG 77 Oncogenex Pharmaceuticals, Inc. 78 Orion Oyj 79 Orphagen Pharmaceuticals, Inc. 80 Oxford BioMedica plc 81 Panacela Labs, Inc. 82 Tokai Pharmaceuticals, Inc. 83 Viamet Pharmaceuticals, Inc. 84 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics Assessment 85 Assessment by Monotherapy Products 85 Assessment by Target 86 Assessment by Mechanism of Action 90 Assessment by Route of Administration 93 Assessment by Molecule Type 95 Drug Profiles 97 AB-3A4 - Drug Profile 97 afatinib - Drug Profile 98 AKAGU-52 - Drug Profile 102 Alecsat - Drug Profile 103 alisertib - Drug Profile 105 AM-0010 - Drug Profile 109 AMG-212 - Drug Profile 110 AMPI-109 - Drug Profile 112 AO-1530 - Drug Profile 113 apatorsen - Drug Profile 114 APH-0701 - Drug Profile 116 AT-001 - Drug Profile 117 AUS-131 - Drug Profile 118 AZD-3965 - Drug Profile 120 AZD-8186 - Drug Profile 121 BAY-1024767 - Drug Profile 122 BCT-100 - Drug Profile 123 BIS-1602 - Drug Profile 125 BPI-5143 - Drug Profile 126 buparlisib hydrochloride - Drug Profile 127 CG-1521 - Drug Profile 131 CIM-1 - Drug Profile 132 Dendritic Cell Therapy to Target Mucin 1 for Prostatic Adenocarcinoma - Drug Profile 133 DendriVax - Drug Profile 134 dexamethasone acetate - Drug Profile 135 EC-1169 - Drug Profile 136 EM-5854 - Drug Profile 137 EN-3356 - Drug Profile 138 enzalutamide - Drug Profile 139 EPI-001 - Drug Profile 142 galeterone - Drug Profile 143 GEN-0101 - Drug Profile 145 GPA-500 - Drug Profile 147 GPA-512 - Drug Profile 148 GPB-600 - Drug Profile 149 GSK-2849330 - Drug Profile 150 GTx-758 - Drug Profile 151 HE-3235 - Drug Profile 152 HyperAcute Vaccine for Prostate Cancer - Drug Profile 154 inecalcitol - Drug Profile 155 ipatasertib - Drug Profile 157 IRX-4204 - Drug Profile 159 ISIS-EIF4ERx - Drug Profile 161 ITK-1 - Drug Profile 163 JNJ-56021927 - Drug Profile 165 KRM-20 - Drug Profile 167 KX-01 - Drug Profile 168 LFA-102 - Drug Profile 170 mepacrine - Drug Profile 172 MIA-602 - Drug Profile 174 MSB-0010718C - Drug Profile 175 MVA-BN-PRO - Drug Profile 176 MVI-118 - Drug Profile 177 ODM-201 - Drug Profile 178 onalespib - Drug Profile 180 onapristone ER - Drug Profile 183 Oncolytic Virus for Glioblastoma Multiforme and Prostate Cancer - Drug Profile 185 ozarelix - Drug Profile 186 pasireotide LAR - Drug Profile 188 Peptide for Androgen-Independent Prostate Cancer - Drug Profile 190 pidilizumab - Drug Profile 191 radium Ra 223 dichloride - Drug Profile 193 rilotumumab - Drug Profile 196 sabarubicin - Drug Profile 198 Small Molecule to Inhibit 17-Beta-HSD for Castration-Resistant Prostate Cancer - Drug Profile 200 Small Molecule to Inhibit Androgen Receptor for Hormone Refractory Prostate Cancer - Drug Profile 201 Small Molecules to Antagonize Androgen Receptor for Castration-Resistant Prostate Cancer - Drug Profile 202 Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease - Drug Profile 203 Small Molecules to Inhibit AKR1C3 for Oncology - Drug Profile 204 solitomab - Drug Profile 205 Somadex - Drug Profile 207 SR-16388 - Drug Profile 208 TeloB-VAX - Drug Profile 210 TroVax - Drug Profile 211 vandetanib - Drug Profile 214 varlilumab - Drug Profile 220 VT-464 - Drug Profile 222 zoptarelin doxorubicin - Drug Profile 223 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Recent Pipeline Updates 225 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects 289 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products 294 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Product Development Milestones 296 Featured News & Press Releases 296 Appendix 305 Methodology 305 Coverage 305 Secondary Research 305 Primary Research 305 Expert Panel Validation 305 Contact Us 306 Disclaimer 306
List of Tables Number of Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H2 2014 17 Number of Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis, H2 2014 18 Number of Products under Development by Companies, H2 2014 20 Number of Products under Development by Companies, H2 2014 (Contd..1) 21 Number of Products under Development by Companies, H2 2014 (Contd..2) 22 Number of Products under Development by Companies, H2 2014 (Contd..3) 23 Number of Products under Investigation by Universities/Institutes, H2 2014 24 Comparative Analysis by Late Stage Development, H2 2014 25 Comparative Analysis by Clinical Stage Development, H2 2014 26 Comparative Analysis by Early Stage Development, H2 2014 27 Comparative Analysis by Unknown Stage Development, H2 2014 28 Products under Development by Companies, H2 2014 29 Products under Development by Companies, H2 2014 (Contd..1) 30 Products under Development by Companies, H2 2014 (Contd..2) 31 Products under Development by Companies, H2 2014 (Contd..3) 32 Products under Development by Companies, H2 2014 (Contd..4) 33 Products under Investigation by Universities/Institutes, H2 2014 35 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2014 36 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Adamis Pharmaceuticals Corporation, H2 2014 37 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Aeterna Zentaris Inc., H2 2014 38 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Alethia Biotherapeutics Inc., H2 2014 39 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Amgen Inc., H2 2014 40 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AnGes MG, Inc., H2 2014 41 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Antoxis Limited, H2 2014 42 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Aphios Corporation, H2 2014 43 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Armour Therapeutics Inc., H2 2014 44 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Arno Therapeutics, Inc., H2 2014 45 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Astellas Pharma Inc., H2 2014 46 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Astex Pharmaceuticals, Inc., H2 2014 47 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AstraZeneca PLC, H2 2014 48 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Ausio Pharmaceuticals, LLC, H2 2014 49 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bavarian Nordic A/S, H2 2014 50 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bayer AG, H2 2014 51 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Beta Pharma, Inc., H2 2014 52 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bio-Cancer Treatment International Limited, H2 2014 53 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Biscayne Pharmaceuticals, Inc., H2 2014 54 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2014 55 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2014 56 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by CureTech Ltd., H2 2014 57 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by CytoVac A/S, H2 2014 58 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by DexTech Medical AB, H2 2014 59 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Enceladus Pharmaceuticals BV, H2 2014 60 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Endo Pharmaceuticals Inc., H2 2014 61 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by EndoCeutics, Inc., H2 2014 62 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Endocyte, Inc., H2 2014 63 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Errant Gene Therapeutics, LLC, H2 2014 64 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Fujifilm Corporation, H2 2014 65 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Genentech, Inc., H2 2014 66 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Glactone Pharma AB, H2 2014 67 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by GlaxoSmithKline plc, H2 2014 68 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by GTx, Inc., H2 2014 69 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Harbor Therapeutics, Inc., H2 2014 70 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Hybrigenics S.A., H2 2014 71 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Incuron, LLC, H2 2014 72 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Io Therapeutics, Inc., H2 2014 73 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Isis Pharmaceuticals, Inc., H2 2014 74 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Johnson & Johnson, H2 2014 75 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Kinex Pharmaceuticals, LLC, H2 2014 76 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Medivation, Inc., H2 2014 77 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Medvio Eurasia, H2 2014 78 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Merck KGaA, H2 2014 79 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 80 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by NewLink Genetics Corporation, H2 2014 81 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Novartis AG, H2 2014 82 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H2 2014 83 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Orion Oyj, H2 2014 84 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2014 85 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Oxford BioMedica plc, H2 2014 86 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Panacela Labs, Inc., H2 2014 87 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Tokai Pharmaceuticals, Inc., H2 2014 88 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Viamet Pharmaceuticals, Inc., H2 2014 89 Assessment by Monotherapy Products, H2 2014 90 Number of Products by Stage and Target, H2 2014 92 Number of Products by Stage and Mechanism of Action, H2 2014 96 Number of Products by Stage and Route of Administration, H2 2014 99 Number of Products by Stage and Molecule Type, H2 2014 101 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics - Recent Pipeline Updates, H2 2014 230 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects, H2 2014 294 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products, H2 2014 299 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products (Contd..1), H2 2014 300
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.